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Summary From July 1977 to July 1983, 120 children with non-Hodgkin's Lymphoma entered a randomised
trial of combination chemotherapy and radiotherapy. The primary site was abdominal in 42 patients,
mediastinal in 27 and in other sites in 51. Failure-free survival (FFS) at 4 years was 74% for the 41 patients
with localised disease (Stages I and II) and 51% for the 79 with generalised disease (Stages III and IV).
Patients with mediastinal primaries continued to relapse after the completion of 2 years' treatment, but FFS
at 4 years for the 93 patients with non-mediastinal primaries was 65% for all stages combined. In the latter
group, there was no benefit to patients randomised at the end of induction chemotherapy to receive adjuvant
radiation 15 Grays in 10 fractions in 2 weeks to sites of previous bulky disease when compared to those not
receiving such radiation (P=0.6).
Lymphomas account for 10 percent of childhood
malignancies with slightly less than half designated
as Hodgkin's disease and the remainder as Non-
Hodgkin's Lymphoma (NHL).
The standard treatment for children with NHL
has been radiation therapy until recent times. Low
dose chemotherapy was given for systemic relapse,
which occurred in the great majority of patients and
the prognosis was uniformly poor. Wollner et al.
(1976) reported that the use of a modified intensive
combination chemotherapy programme initially
designed for the treatment of children with acute
lymphoblastic leukaemia (ALL), had resulted in a
substantial improvement in prognosis for children
with NHL. Their results have been confirmed by
others using similar treatment programmes.
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The role of radiation therapy when combined
with such chemotherapy schedules has been the
subject of considerable controversy. In such a rare
group of diseases, it was clear that a multi-centre
trial would be necessary to accrue sufficient
numbers of patients for randomised studies and yet
in that context it was not thought possible to
administer safely both standard radiation and
standard combination chemotherapy without
compromising one or other modality. The design of
one trial (Murphy & Hustu, 1980) in which
standard radiation during induction was evaluated
in conjunction with a continuous leukaemia-type
maintenance chemotherapy schedule prompted us
to develop a complementary trial in which a rather
more intensive intermittent lymphoma
chemotherapy schedule was combined with low
dose radiation given during consolidation as an
adjuvant.
Patients and methods
NHL is an heterogeneous group of disorders and it
is therefore difficult to ensure reproducible criteria
for inclusion and exclusion of patients in a multi-
centre trial. The composition of groups of such
patients may therefore differ considerably from one
series to another. In order to minimise this
potential for bias participating members were
encouraged to register all patients with NHL on the
study, and if possible to treat them according to the
trial protocol, so that it might be possible
subsequently to define those factors which
significantly affect prognosis.
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All patients entered into the randomised trial
required histological and/or immunocytochemical
documentation of their disease, and review of the
histopathology was undertaken by Dr A. Stansfeld,
St Bartholomews' Hospital, London. When possible,
immune marker studies were also done, though
patients were often not referred to participating
clinicians until after diagnosis had been established
on formalin fixed tissues. Preliminary results of
some of the immune marker studies have already
been published (Habeshaw, 1980).
The extent of disease at diagnosis was categorized
according to the St Jude staging system (Table I), in
which all patients with mediastinal or abdominal
primaries are automatically excluded from Stage I
and all intrathoracic tumours and extensive intra-
abdominal tumours are automatically categorized
as Stage III. CNS involvement or bone marrow
involvement with <25% blasts in an otherwise
normal aspirate and with a normal peripheral blood
picture was categorized as Stage IV, and those
patients with >25% blasts in marrow or blasts
present in peripheral blood were designated as
having leukaemia and were therefore excluded from
the trial (Table II). Marrow aspirate and trephine
were required from a minimum of two sites since
patchy involvement of marrow is well documented
in childhood lymphomas.
Table I St Jude staging system
STAGE I
A single tumour (extranodal) or single anatomic area
(nodal), with the exclusion ofmediastinum or abdomen.
STAGE II
A single tumour (extranodal) with regional node
involvement.
Two or more nodal areas on the same side of the
diaphragm.
Two single (extranodal) tumours with or without
regional node involvement on the same side of the
diaphragm.
A primary gastrointestinal tract tumour, usually in the
ileocaecal area, with or without involvement of
associated mesenteric nodes only.
STAGE III
Two single tumours (extranodal) on opposite sides of
the diaphragm.
Two or more nodal areas above and below the
diaphragm.
All the primary intra-thoracic tumours (mediastinal,
pleural, thymic).
All extensive primary intra-abdominal disease.
All paraspinal or epidural tumours, regardless of other
tumour site(s).
STAGE IV
Any of the above with initial CNS and/or bone marrow
involvement.
Table II Reasons for exclusion from Trial
Patients
Histology:
Malignant histiocytosis
Ewing's tumour
Thymoma
Granulocytic sarcoma
No histology
Uncertain histology
Associated conditions:
Bloom's syndrome
Ataxia telangiectasia
Sibling with ataxia telangiectasia
Leukaemic at diagnosis
Previous treatment
Elective radiotherapy in induction
Age (5 months and 18 years)
Not randomised
Gross protocol violation
6
3
2
1
1
1 14
1
1
1 3
13
8
4
2
2
2
Total 48
All patients were evaluated for the extent of their
disease with a minimum of a complete history and
physical examination, full blood count, bone
marrow aspirate and trephine, lumbar puncture
with cytocentrifugation of CSF for white cell
morphology, and chest X-ray.
The majority of patients with disseminated
disease were staged and started on treatment within
48 h of referral. Those patients with apparently
localised disease were subjected to a more rigorous
staging investigation including, where necessary,
lymphangiography, CT scanning and laparotomy.
This was regarded as particularly important when
the definition of extent of disease determined a
significant alteration in the treatment offered, as
was the case in this trial for Stage I disease. Stage II
for patients with abdominal primaries requires
laporotomy and resection of localised disease.
Survival and failure-free survival curves were
calculated by the life-table method and compared
using the logrank test (Peto et al., 1977).
Failure-free survival (FFS) denotes the period
from entry into the study to the occurrence of any
adverse event, such as failure to enter complete
remission by the end of the induction phase, relapse
or death.
The trial protocols
The primary objective for Stage I patients was to
determine whether initial treatment should be with
radiation alone, or radiation plus short-term
combination chemotherapy. Patients thereforeLOW DOSE RADIATION IN CHILDHOOD LYMPHOMA 465
received 30 Gy in 3 weeks (2Gy per fraction, 5 days
per week) to the involved field and were randomly
assigned to additional COP (Cyclophosphamide,
Oncovin, Prednisolone) chemotherapy every 3
weeks for 10 doses, or no further treatment, the first
dose of COP being given on day 1 of radiation and
the second dose being given on completion (Table
III).
All other patients were treated with a
combination chemotherapy programme (Table IV
and Figure 1). Emergency radiation (1.5 Gy x 3) was
permissible for patients with life-threatening local
disease at presentation such as respiratory distress
or superior vena caval obstruction from a
mediastinal mass or bilateral renal infiltration
+ureteric obstruction. Patients who successfully
completed the induction phase were randomly
Table III Treatment of Stage I disease
RADIATION 30.0Gy in 3 weeks I.F.
+CHEMOTHERAPY
COP 3 weekly x 10 courses
1st course commences on day 1 of RT
2nd course commences on last day of RT
CYCLOPHOSPHAMIDE 1 gm- i.v.
VINCRISTINE 1.5mgm-2 i.v.
PREDNISOLONE lOOmgm-2 p.o. days 1 to 5
Table IV Treatment for Stages II-IV
Induction
1. CHOP
Cyclophosphamide
Adriamycin
Vincristine
Prednisolone
2. Cyt/TG
Cytosine arabinoside
Thioguanine
3. Intrathecal methotrexate
1gm-2
50 mgm 2 Day 1
1.5mgm 2
100mgm-2 Days 1-5
Given every 3 weeks for 2 cycles
-2 100mgm i.v. or s.c. 12 hourly for 8 doses
75 mgm-2 p.o. daily for 4 doses
Given every 3 weeks for 2 cycles
10 mg m-2 (maximum 12mg) on Day 1 of each course
Consolidation
1. Methotrexate, 500mgm 2 (one-third i.v. push two-thirds i.v. drip over 6 h)
2. 24h after the beginning of the infusion, folinic acid 12mgm-2 i.m. or i.v. followed by 3 doses 6mgm-2 (i.v. or
oral) over the next 24h
3. Intrathecal methotrexate 10mgm-2 at the start of i.v. methotrexate infusion
Given every 2 weeks for 3 cycles.
Randomisation
With or without 15 Gy of radiotherapy in 10 fractions over 2 weeks to areas of bulky disease concurrently with
consolidation chemotherapy.
N.B. Special category for patients with Sternberg sarcoma
1. Methotrexate 15mgm 2 oral daily x 4 every 2 weeks x 3 instead ofi.v. methotrexate
2. Intrathecal methotrexate on Day 1 of each course
3. Cranial radiation, 17.6Gy in 8 fractions of 2.2Gy over 2 weeks
Maintenance
1. Cyclophosphamide/CCNU
Cyclophosphamide 750mgm2
CCNU 75 mgm-2 p.o.
2. VM26 100mgm-2 i.v.
Methotrexate 500mgm2 i.v. with citrovorum factor rescue (as in consolidation)
NB For patients with Sternberg sarcomas who have received cranial radiation, methotrexate will not be given i.v.
but orally at a dose of 12.5 mgm2 daily for 4 days.
3. CHOP
Cyclophosphamide 750mgm-2 (adriamycin 40mgm 2)
4. Cytosine arabinoside/thioguanine
Cytosine arabinoside 150mgm-2 i.V. or s.c. Daily x 5 days
Thioguanine 75mgm2 p.o.
Given at 3 week intervals. Twelve week maintenance cycle for 2 years.466 M.G. MOTT et al.
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Figure 1 Treatment schema.
assigned at the beginning of consolidation to receive
either 15 Gy of radiotherapy in 10 fractions over 2
weeks to areas where there had been bulk disease at
the time of diagnosis or no adjuvant radiotherapy.
All patients received CNS prophylaxis with
intrathecal methotrexate commencing on day 1 and
throughout treatment with a number of
chemotherapeutic agents known to cross the blood
brain barrier. Patients with T cell lymphoma (i.e.
those with a mediastinal primary, otherwise known
as Sternberg Sarcoma) received in addition cranial
radiation 17.6 Gy (8 fractions of 2.2 Gy) during the
first 2 weeks of the consolidation phase of
treatment. These patients received oral instead of
i.v. methotrexate during both consolidation and
maintenance phases of treatment to avoid the risk
of leucoencephalopathy.
Results
From July 1977 to July 1983, 250 patients were
registered from 18 participating centres. Six of the
larger centres used an intensive variant of the trial
protocol for 82 patients with T cell disease
irrespective of whether this was defined as
lymphoma or leukaemia, and the results of that
trial are published separately (Mott et al., 1984).
Forty-eight other patients registered on the study
were excluded from the trial for the reasons
indicated in Table II.
Thus 120 patients were eligible for entry into the
NHL trial. There were 97 boys and 23 girls with an
age-range from 2-14 years at diagnosis, the male
predominance being as expected from all other
studies of this disorder in childhood.
Seven patients had Stage I disease, 34 patients
Stage II, 63 patients Stage III and 16 patients Stage
IV. The primary site of disease was abdominal in 42
patients, mediastinal in 27 patients, and in other
sites in 51 patients.
Life-table survival and FFS curves for all patients
are shown in Figure 2. FFS at 4 years was 83% for
Stage I, 72% for Stage II, 51% for Stage III and
56% for Stage IV (P value for trend=0.1).
FFS at 4 years was 74% for patients with
localised disease (Stages I and II) compared to 51%
for those with generalised disease (Stages III and
IV) (P=0.05).
Prognosis was clearly related to the site of
presentation. For the 42 patients with an abdominal
primary, FFS at 4 years was 69% and for the total
of 93 patients with primary disease in sites other
than the mediastinum, FFS at 4 years was 65% and
overall survival 70% with a plateau from 33
months.
FFS curves for these patients randomised to
receive or not to receive low dose radiation are
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shown in Figure 3. The pattern of relapse according
to site is shown in Table V.
In contrast, FFS for the 27 patients with
mediastinal primaries was only 39%. They
continued to relapse throughout the third and
fourth years. The results for these mediastinal
patients are presented in more detail in a
companion analysis, together with those entered on
the more intensive T cell protocol (Mott et al.,
1984).
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Figure 2 Life-table survival (...) and failure-free (-)
survival for all Trial patients.
luu
80
4)
cL
a)
0-
60
40
20
0 12 24 36
Time (months)
48
Figure 3 Failure-free survival for 82 non mediastinal
patients randomly assigned to adjuvant radiotherapy
(...) or not ( ).
Table V Childhood NHL (120 patients). Pattern of 1st
event (44) by primary site
Abdominal Mediastinal Other
(42) (27) (51)
BM relapse 1 2 8
BM+CNS relapse 1 0 1
CNS relapse 3 3 1
Local relapse 3 5 3
Death before remission 4 0 2
Death in remission 0 0 1
Testicular relapse 0 2 0
Other relapse 1 2 1
Totals 13 14 17
This trial confirms that combination chemotherapy
should be the primary treatment modality for
childhood NHL, and that the majority of such
patients should now be long-term survivors.
The pilot studies on which this trial was based
(Wilson et al, 1977; Goldman et al, 1981) were
initiated at the same time as another trial in which
patients with advanced disease were randomised to
receive or not to receive 30-35 Gy to areas of bulk
disease during induction chemotherapy, combined
with a more gentle maintenance chemotherapy
programme (Murphy & Hustu, 1980).
The results of that trial showed no benefit to the
patients who received radiation at the onset of
treatment in higher doses than in this trial. In
addition a smaller proportion of patients with
disseminated disease survived relapse-free in the
long term. Thus neither standard dose radiation
given at the time of diagnosis nor low dose
radiation given at the time of consolidation
appeared to confer any benefit to the patient in
these studies. The well documented hazards of
second malignant neoplasms occurring in
lymphoma patients who have had both
chemotherapy and radiotherapy (Donaldson &
Kaplan, 1982), is an additional argument for
minimising radiotherapy in patients treated
primarily with combination chemotherapy and for
giving it only when essential.
Patients whose treatment fails and whose disease
progresses usually have systemic relapse, with
spread to bone marrow and/or central nervous
system or other sanctuary sites. This suggests that
the correct strategy for most patients is to intensify
chemotherapy rather than to increase treatment to
the local area, which would certainly compromise
tolerance for further intensive chemotherapy.
The lower rate of relapse in patients with truly
localised disease, i.e. Stage I, coupled with the
capacity to eradicate disseminated disease in a
substantial proportion of patients suggests that a
policy of using involved field radiation alone in the
first instance might possibly be appropriate for
highly selected patients with apparently localised
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disease, reserving chemotherapy for those who show
subsequent evidence of dissemination. The number
of patients required to establish this point makes it
impractical to consider further except in the context
of an international study. The role of radiotherapy
in the overwhelming majority of patients with more
advanced disease, is however, clearly called into
question.
Of the 42 patients with abdominal primaries,
there was failure to control their disease in 13
(Table V). Two patients died of biochemical
problems, hyperkalaemia on day 1, and urate
nephropathy on day 9. Two patients developed
local regrowth during the induction period and
three soon afterwards (2, 2.5, 3, 4.5, 11 months from
diagnosis) and they survived 4.5, 5, 6, 6 and 15
months. Clearly the major problem for patients
with abdominal lymphoma was failure to control
local disease, though systemic spread to CNS and
bone marrow despite systemic and intrathecal
chemotherapy occurred also. Local radiation
appeared to make no difference, whether given
during induction, as in the St Jude trial (Murphy &
Hustu, 1980), or during consolidation as in our
patients.
There were only 2 relapses later than 12 months
which suggests that one year of this type of
treatment might be sufficient for this group of
patients.
The behaviour of the patients with mediastinal
primaries, who nearly all have T cell Lymphoma
(Bernard et al., 1982) was different. These patients
continued to suffer relapse throughout the two year
period of chemotherapy and subsequently on both
the NHL and the intensified T cell protocols. The
implications for future treatment of T cell disease
are discussed in the companion report (Mott et al.,
1984).
It is now well established that the great majority
of patients with mediastinal primaries have T cell
lymphoma, whereas those with abdominal primaries
have B cell lymphoma (Bernard et al., 1982), so the
finding that their responses to the same treatment
regimen are different is not particularly surprising.
A histological corollary of this is the finding in the
CCSG trial that different chemotherapy protocols
were effective for lymphoblastic versus other
histological categories of non-Hodgkin's lymphoma
of childhood (Anderson et al., 1983).
The toxicity of this treatment programme was
variable as might be anticipated from such a
complex schedule. Half of the patients required a
15% or greater reduction in chemotherapy at some
stage in their programme, and both survival and
FFS were substantially better in that group when
compared to those not reported to require dose
modifications. The same was true for patients on
the more intensive T cell protocol (Mott et al.,
1984) and the difference for both trials combined is
highly significant. The types of toxicity encountered
and their relationship to prognosis will be the
subject of a separate report.
The success of this treatment regimen for patients
with disseminated disease, particularly those
without mediastinal primaries, whether or not they
received adjuvant radiation, suggests that exposure
of these patients to radiation and the attendant
foreseeable hazards of combined radi-
ation/chemotherapy is unnecessary in most
instances. The fact that all the patients in the
CCSG trial were exposed to both radiation and
combination chemotherapy, as were half of the
patients in our trial, must give rise to some concern
that second malignant neoplasms may occur in the
survivors (Donaldson & Kaplan, 1977).
Clear-cut differences in response to treatment are
now apparent in a number of subgroups of children
with NHL. New treatment strategies based on
immunopathological classification, primary site and
disease extent are required if results are to be
improved further and these will be incorporated in
the next generation of trials for these conditions.
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